The gap between approval and access

A positive regulatory decision is the first step of a UK launch. The NHS operates as a layered system: NICE guidance sits above NHS England commissioning policy, Integrated Care Boards(ICBs), and individual hospital formularies, each with its own timeline, criteria and decision-makers. Without existing relationships at any of these levels, a new market entrant has to navigate them all at once.

Companies launching in the UK for the first time typically face:

No existing relationships with ICBs, NHS Trusts orclinical teams

Limited visibility into NHS commissioning, formulary and budget cycles

No infrastructure to recruit, employ or manage UK-based staff

Unfamiliarity with UK employment law, clinical governance and compliance requirements

Une expertise éprouvée sur le marché qui compte pour vous

Six weeks

average time to buildand deploy a field-ready team

90%

team retention rate after 12 months

25+

years workingexclusively in UK life sciences
Trusted by AstraZeneca, GSK, Novo Nordisk, Roche and other global pharmaceutical and medtech companies entering or operating inthe UK

“I didn't think it would be possible to source such a high-quality team in such a short time. We worked as a true partnership, and I believe we have the best possible team for our launch.”

Sales & Marketing Director

working with CHASE on an oncology launch
A man smiling at his computer